CAR T cells have achieved success in certain hematological malignancies, including relapsed acute lymphoblastic leukemia (ALL) and refractory chronic lymphocytic leukemia (CLL), resulting in recent FDA approval of two CD19-targeting CAR products (45). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.